Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I randomized, crossover , and single dose trial comparing safety, tolerance, and pharmacodynamics characteristics of SOL-804 to Zytiga

Next Previous
Trial Profile

A phase I randomized, crossover , and single dose trial comparing safety, tolerance, and pharmacodynamics characteristics of SOL-804 to Zytiga

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Abiraterone acetate
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bukwang Pharmaceutical

Most Recent Events

  • 30 Mar 2022 New trial record
  • 25 Mar 2022 According to Bukwang Pharm media release, this trial has been completed.; this clinical trial is to confirm at what dose SOL-804 has improved the absorption rate of existing drugs, Bukwang Pharm plans to conduct clinical trials for approval after determining the dose based on this trial clinical results expected to be confirmed in March

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top